Concomitant psychotropic medication use during treatment of schizophrenia patients: Longitudinal results from the CATIE study

Clinical Schizophrenia and Related Psychoses

Volumn 5, Issue 3, 2011, Pages 124-134

  Chakos, Miranda ^a   Patel, Javendra K ^b   Rosenheck, Robert ^c   Glick, Ira D ^d   Hamner, Mark B ^e   Miller, Del D ^f   Tapp, Andre ^g   Miller, Alexander ^h  

^a NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Antipsychotic; Concomitant medication; Psychopharmacology; Schizophrenia

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BUSPIRONE; CHLORAL HYDRATE; CHLORDIAZEPOXIDE; CITALOPRAM; CLONAZEPAM; CLORAZEPATE DIPOTASSIUM; DIAZEPAM; ESCITALOPRAM; FLUOXETINE; FLURAZEPAM; HYDROXYZINE; HYPNOTIC SEDATIVE AGENT; IMIPRAMINE; LORAZEPAM; MIRTAZAPINE; OLANZAPINE; OXAZEPAM; PAROXETINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; TEMAZEPAM; TRAZADONE; UNCLASSIFIED DRUG; VENLAFAXINE; ZIPRASIDONE; ZOLPIDEM; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADD ON THERAPY; ADULT; AFRICAN AMERICAN; AGED; AKATHISIA; ALCOHOL ABUSE; ALCOHOLISM; ANXIETY; ANXIETY DISORDER; ARTICLE; BODY MASS; CAUCASIAN; COGNITION; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DIVORCE; DRUG EFFICACY; DRUG USE; EDUCATIONAL STATUS; FEMALE; HUMAN; INSOMNIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; POST HOC ANALYSIS; PSYCHIATRIC DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT DURATION; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; RISK FACTOR; SOCIOECONOMICS;

ADULT; ALCOHOLISM; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; COMORBIDITY; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PERPHENAZINE; PSYCHOTROPIC DRUGS; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIOECONOMIC FACTORS;

EID: 84856384130     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.5.3.2     Document Type: Article

References (64)

1. Novick D, Bousono M, Suarez D, Olivares JM, Montejo AL, Haro JM, et al. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study. Prog Neuropsychopharmacol Biol Psych 2005;29(6):972-982. (Pubitemid 41080120)
2. Parepally H, Chakravorty S, Levine J, Brar JS, Patel AM, Baird JW, et al. The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents: a naturalistic study at a state psychiatric hospital. Prog Neuropsychopharmacol Biol Psychiatry 2002;26(3):437-440. (Pubitemid 34252935)
3. Sacristan JA, Gomez JC, Montego AL, Vieta E, Gregor KJ. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapine. Clin Ther 2000;22(5):583-599. (Pubitemid 30434311)
4. Williams CL, Johnstone BM, Kesterson JG, Javor KA, Schmetzer AD. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care 1999;37(4 Suppl Lilly):AS81-AS86.
5. Rittmannsberger H, Meise U, Schauflinger K, Horvath E, Donat H, Hinterhuber H. Polypharmacy in psychiatric treatment: patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 1999;14(1):33-40.
6. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 2003;12(1):41-48. (Pubitemid 36192948)
7. Wolkowitz OM, Pickar D. Benzodiazepine in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991;148(6):714-726.
8. Glick ID, Zaninelli R, Hsu C, Young FK, Weiss L, Gunay I, et al. Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior. J Clin Psychiatry 2004;65(5):679-685.
9. dosReis S, Zito JM, Buchanan RW, Lehman AF. Antipsychotic dosing and concurrent psychotropic treatments for Medicaid-insured individuals with schizophrenia. Schizophr Bull 2002;28(4):607-617. (Pubitemid 36569790)
10. Acquaviva E, Gasquet I, Falissard B. Psychotropic combination in schizophrenia. Eur J Clin Pharmacol 2005;61(11):855-861. (Pubitemid 41720275)
11. Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 2006;57(8):1094-1101. (Pubitemid 44204901)
12. Edlinger M, Hausmann A, Kemmler G, Kurz M, Kurzthaler I, Walch T, et al. Trends in the pharmacological treatment of patients with schizophrenia over a 12-year observation period. Schizophr Res 2005;77(1):25-34. (Pubitemid 40957058)
13. Ratner Y, Gibel A, Yorkov V, Ritsner MS. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(7):1401-1409. (Pubitemid 47302551)
14. Brunot A, Lachaux B, Sontag H, Casadebaig F, Philippe A, Rouillon F, et al. [Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: Patient characteristics, antipsychotic treatment, and care management for schizophrenia]. Encephale 2002;28(2):129-138. French.
15. Fourrier A, Gasquet I, Allicar MP, Bouhassira M, Lepine JP, Begaud B. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol 1999;49(1):80-86. (Pubitemid 30050490)
16. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al.; Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-1223.
17. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCID-CV). Washington (DC): American Psychiatric Press; 1997.
18. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13(2):261-276. (Pubitemid 18039085)
19. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: The Calgary Depression Scale. Br J Psychiatry Suppl 1993;(22):39-44. (Pubitemid 23355888)
20. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10(3):388-398.
21. Lehman A. A quality of life interview for the chronically mentally ill. Evaluation and Program Planning 1988;11:51-62.
22. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676. (Pubitemid 19154942)
23. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19.
24. Guy W, editor. ECDEU assessment manual for psychopharmacology. Publication ADM 76-338. Washington (DC): U.S. Department of Health, Education, and Welfare; 1976. p.217-222.
25. Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006;31(9):2033-2046.
26. Montgomery SA, van Zwieten-Boot B. ECNP consensus meeting. Negative, depressive, and cognitive symptoms of schizophrenia. Nice, March 2004. Eur Neuropsychopharmacol 2007;17(1):70-77. (Pubitemid 44802759)
27. Siris SG. Managing depression in schizophrenia. Psychiatric Annals 2005;35(1):60-69. (Pubitemid 40186667)
28. Rocca P, Bellino S, Calvarese P, Marchiaro L, Patria L, Rasetti R, et al. Depressive and negative symptoms in schizophrenia: different effects on clinical features. Compr Psychiatry 2005;46(4):304-310. (Pubitemid 40814450)
29. Addington D, Addington J, Patten S. Gender and affect in schizophrenia. Can J Psychiatry 1996;41(5):265-268. (Pubitemid 26242430)
30. Myin-Germeys I, Krabbendam L, Delespaul PA, van Os J. Sex differences in emotional reactivity to daily life stress in psychosis. J Clin Psychiatry 2004;65(6):805-809.
31. Killgore WD, Oki M, Yurgelun-Todd DA. Sex-specific developmental changes in amygdala responses to affective faces. Neuroreport 2001;12(2):427-433. (Pubitemid 32114392)
32. Drake RJ, Pickles A, Bentall RP, Kinderman P, Haddock G, Tarrier N, et al. The evolution of insight, paranoia, and depression during early schizophrenia. Psychol Med 2004;34(2):285-292. (Pubitemid 38239636)
33. Crumlish N, Whitty P, Kamali M, Clarke M, Browne S, McTigue O, et al. Early insight predicts depression and attempted suicide after 4 years in first-episode schizophrenia and schizophreniform disorder. Act Psychiatr Scand 2005;112(6):449-455. (Pubitemid 41676689)
34. Turkington A, Mulholland CC, Rushe TM, Anderson R, McCaul R, Barrett SL, et al. Impact of persistent substance misuse on 1-year outcome in first-episode psychosis. Br J Psychiatry 2009;195(3):242-248.
35. Ukai W, Ishii T, Hashimoto E, Tateno M, Yoshinaga T, Ono T, et al. The common aspects of pathophysiolgy of alcoholism and depression. Nihon Arukoru Yakubutsu Igakkai Zasshi 2009;44(6):704-711.
36. Prince JD. Education, ethnicity, and subjective life quality of recently discharged inpatients with schizophrenia. J Nerv Ment Dis 2007;195(7):560-565. (Pubitemid 47067466)
37. Ginsberg LD. Impact of drug tolerability on the selection of antidepressant treatment in patients with major depressive disorder. CNS Spectr 2009;14(12 Suppl 12):8-14.
38. Lee KU, Lee YM, Nam JM, Lee HK, Kweon YS, Lee CT, et al. Antidepressant-induced sexual dysfunction among newer antidepressants in a naturalistic setting. Psychiatry Investigation 2010;7(1):55-59.
39. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991;148(6):714-726.
40. Simon GE, Von Korff M, Saunders K, Miglioretti DL, Crane PK, van Belle G, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry 2006;63(7):824-830.
41. Kress AM, Peterson MR, Hartzell MC. Association between obesity and depressive symptoms among U.S. military active duty service personnel, 2002. J Psychosom Res 2006;60(3):263-271. (Pubitemid 43325316)
42. Onyike CU, Crum RM, Lee HB, Lyketsos CG, Easton WW. Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2003;158(12):1139-1147. (Pubitemid 37548783)
43. Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P, Juneja M, et al. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 2002;106(21):2659-2665. (Pubitemid 35364919)
44. Chandola T, Brunner E, Marmot M. Chronic stress at work and the metabolic syndrome: prospective study. BMJ 2006;332(7540):521-525.
45. Jorm AF, Korten AE, Christensen H, Jacomb PA, Rodgers B, Parslow RA. Association of obesity with anxiety, depression and emotional well-being: a community survey. Aust N Z J Public Health 2003;27(4):434-440. (Pubitemid 37038226)
46. Skilton MR, Moulin P, Terra JL, Bonnet F. Association between anxiety, depression, and metabolic syndrome. Biol Psychiatry 2007;62(11):1251-1257. (Pubitemid 350060887)
47. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 2005;28(3):191-208. (Pubitemid 40364887)
48. Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TR. Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 2002;(1):CD001950.
49. Acevedo SF, Pfankuch T, Ohtsu H, Raber J. Anxiety and cognition in female histidine decarboxylase knockout (Hdc(-/-) mice. Behav Brain Res 2006;168(1);92-99. (Pubitemid 43153771)
50. Siegel JA, Haley GE, Raber J. Apolipoprotein E isoform-dependent effects on anxiety and cognition in female TR mice. Neurobiol Aging 2010 Apr 16. Epub ahead of print.
51. Craig D, Passmore AP, Fullerton KJ, Beringer TR, Gilmore DH, Crawford VL, et al. Factors influencing prescription of CNS medication in different elderly populations. Phamacoepidemiol Drug Saf 2003;12(5):383-387. (Pubitemid 36903373)
52. Cohrs S. Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics. CNS Drugs 2008;22(11):939-962.
53. Haffmans PM, Hoencamp E, Knegtering HJ, van Heycop ten Ham BF. Sleep disturbance in schizophrenia. Br J Psychiatry 1994;165(5):697-698.
54. Ritsner M, Kurs R, Ponizovsky A, Hadjez J. Perceived quality of life in schizophrenia: relationships to sleep quality. Qual Life Res 2004;13(4):783-791. (Pubitemid 38509978)
55. Van Mill JG, Hoogendijk WJ, Vogelzangs N, van Dyck R, Penninx BW. Insomnia and sleep duration in a large cohort of patients with major depressive disorder and anxiety disorders. J Clin Psychiatry 2006;67(8):1261-1265.
56. Daumit GL, Crum RM, Guallar E, Powe NR, Primm AB, Steinwachs DM, et al. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States. Arch Gen Psychiatry 2003;60(2):121-128. (Pubitemid 36173118)
57. Glazer WM, Morgenstern H, Doucette J. Race and tardive dyskinesia among outpatients at a CMHC. Hosp Community Psychiatry 1994;45(1):38-42. (Pubitemid 24026567)
58. Mallinger JB, Lamberti SJ. Racial differences in the use of adjunctive psychotropic medications for patients with schizophrenia. J Ment Health Policy Econ 2007;10(1):15-22. (Pubitemid 46605737)
59. Mallinger JB, Fisher SG, Brown T, Lamberti JS. Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr Serv 2006;57(1):133-136. (Pubitemid 43053850)
60. Snowden LR. Bias in mental health assessment and intervention: theory and evidence. Am J Public Health 2003;93(2):239-243. (Pubitemid 36159388)
61. Kreyenbuhl J, Zito JM, Buchanan RW, Soeken KL, Lehman AF. Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull 2003;29(2):183-193. (Pubitemid 37187683)
62. Tsimtsiou Z, Ashworth M, Jones R. Variations in anxiolytic and hypnotic prescribing by GPs: a cross-sectional analysis using data from the UK Quality and Outcomes Framework. Br J Gen Pract 2009;59(563):e191-198.
63. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63(10):892-909. (Pubitemid 35231730)
64. Glick ID, Pham D, Davis JM. Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia. J Clin Psychiatry 2006;67(8):1261-1265.